Light-activated nanocarriers for drug release in the eye
Macular degeneration and glaucoma are age-related eye diseases which are expected to increase in prevalence due to the rise in the ageing population. Since these diseases impair vision and hence quality of life, there is a need for efficient administration of therapeutics. The key objective of the EU-funded Light4Sight project is to develop a nanotechnology-based drug delivery system that contains therapeutic peptides within a light-sensitive hydrogel. The hydrogel can be injected in the vitreous, the clear gel that fills the space between the lens and the retina. Drug release will be activated by visible light in a controlled manner, avoiding toxicity while increasing the half-life of the therapeutic.